Ivermectin: Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 | 2022

As of January 2022, there are more than 80 on-going trials globally on Ivermectin for treatment and prevention of COVID-19 on covid-nma.com.

Source: covid-nma.com

Ivermectin is an anti-parasitic medication widely used in low and middle-income countries (LMIC) to treat parasitic worm infections in adults and children. It’s been used for decades for this purpose by over 3.7 billion people, and is considered safe and effective. It has an increasing list of indications due to its antiviral and anti-inflammatory properties, and is included on the WHO’s Model List of Essential Medicines.

In April last year, a trial at Melbourne’s Monash University reported doses of ivermectin stopped or slowed the spread of COVID-19 infection in the lab environment. The researchers said the findings could not be immediately applied to humans but the drug still surged in popularity across Peru, Bolivia, Guatemala and other Latin American countries.

The medical community is battling over whether ivermectin should be used to treat and prevent COVID-19. On one side are experts telling you that more research is needed before the treatment can be fully authorised and confirmed. On the other, are experts telling you that the potential benefits outweigh the risk and a 'wait and do nothing' position is not acceptable. Confused? 

Hopefully, this article can help you make sense of the options and to separate the facts from fiction.

Ivermectin and COVID-19 Updates:

June 17, 2021: Ivermectin for Prevention and Treatment of COVID-19 Infection (Tess Lawrie Ivermectin Meta Analysis)

A Cochrane-standard (=highest) review and meta-analysis of Ivermectin against Covid-19 by Bryant-Lawrie, now peer-reviewed and published, concludes that the evidence justify the global adoption.

June 7, 2021: Epidemiologic Analyses on Ivermectin and COVID-19.

Results of Ivermectin's success in treating COVID-19 outbreaks in India, Mexico, Peru, Paraquay, Argentina, Brazil and Slovakia.

June 1, 2021: The Drug that Obliterates 97% of New Delhi Cases by Justus R. Hope, MD

May 31, 2021: COVID deaths plunge after Mexico City introduces Ivermectin (WND.com)

May 19, 2021 - A study by Juan Chamie, Jennifer Hibberd of the University of Toronto and David Scheim of the US Public Health Service, shows the sharp rise, fall and resurgence in excess deaths (among the over 60 year-old cohort) in Peru as the virus waxed, waned and waxed again.

May 16, 2021: Do the NIH and WHO COVID treatment recommendations need to be fixed? By Steve Kirsch. Published on TrialSiteNews.
Great article on where we stand on the COVID-19 treatment front debate - COVID19Crusher

May 03, 2021 - Joint Statement on Widespread Use of Ivermectin in India for Prevention and Early Treatment by U.K. Evidence-Based Medicine Consultancy Ltd (E-BMC Ltd) and U.S. FLCCC (Front Line Critical Care Alliance).

Apr 26, 2021: The new FLCCC outpatient protocol (I-MASK+) with the addition of fluvoxamine and nasal/oral "sanitation". Fluvoxamine 50 mg twice daily for 10–14 days. Add to ivermectin if: 1) minimal response after 2 days of ivermectin; 2) in regions with more aggressive variants; 3) treatment started on or after day 5 of symptoms or in pulmonary phase; or 4) numerous co-morbidities/risk factors. Avoid if patient is already on an SSRI (Selective Serotonin Reuptake Inhibitor).

Apr 26, 2021: The new FLCCC hospital treatment protocol (MATH+) with the notable additions of Fluvoxamine and anti-androgen therapy (Dutasteride/Finasteride).

April 24, 2021 - The All India Institute of Medical Sciences and Indian Council of Medical Research (ICMR) have issued new guidelines for COVID-19 treatment based on three levels of seriousness--mild, moderate and severe:

Apr 14, 2021: Open Letter by U.S. Doctors: JAMA Ivermectin Study (Lopez-Medina et al) Is Fatally Flawed, TrialSiteNews reported.

Apr 9, 2021: FLCCC (Front Line Critical Care Alliance) statement on Washington Post article.

Apr 1, 2021: WHO reaches ivermectin recommendation without a vote, TrialSiteNews reported.

Mar 31, 2021: FLCCC (Front Line Critical Care Alliance) statement on WHO's Ivermectin guide.

Mar 5, 2021: [Europe] Ivermectin is now approved for COVID-19 use in 2 European countries: Czech Republic and Slovakia.

Feb 25, 2021: Drug used to treat lice and scabies drug could cut Covid deaths by up to 75%, research suggests, DailyMail reported (more than 16,000 shares).

Feb 25, 2021: Scabies and head lice drug could be 'global solution to the pandemic' says study; Mirror UK reported.

Jan 23, 2021: Researchers at Oxford University are planning the first, large high-quality trial of Ivermectin that has been credited with dramatically reducing Covid-19 deaths in the developing world. The PRINCIPLE trial is aiming to find a drug that works soon after virus symptoms appear in a patient, and one that is most effective during the primary stages of the illness, The Times reported.

Jan 19, 2021: A pilot study published in the Lancet on January 19, 2021 showed some promising results but the authors concluded that the study warrants further exploration under larger trials with clinical outcomes in patients with risk factors or more severe disease.

Jan 18, 2021: Updated version of Frequently Asked Questions on Ivermectin in COVID-19 by the FLCCC.

Jan 14, 2021: The National Institutes (NIH) has issued a new statement on the use of the anti-parasitic drug ivermectin for the treatment of COVID-19. Previously, it recommended against this treatment, but now states that its Panel “has determined that there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

Jan 13, 2021: The BIRD meeting (British Ivermectin Recommendation Development) was convened by Dr. Tess Lawrie in order to present the findings from her rapid systematic review and meta-analysis of studies on the use of ivermectin to prevent and treat COVID-19. Dr. Lawrie presented evidence in the form of a DECIDE evidence-to-decision framework, a format used by the World Health Organization for the development of guidelines and recommendations in medical practice. Twenty experts from around the world and the UK attended the meeting, including 13 clinicians, and seven representatives from the public.

Dec 30, 2020: An essential updated review of COVID-19 early-treatment best practices was published. (abstract | PDF | HTML)

This international collaboration — comprised of physicians, like lead author Peter McCullough, MD, courageously treating patients despite the prevalence of “therapeutic nihilism” among government agencies like the NIH and FDA — outlines the urgency of, “prompt early initiation of sequenced multidrug therapy (SMDT) … to stem the tide of hospitalizations and death.”

The authors wrote: 

The early stage of viral replication provides a therapeutic window of tremendous opportunity to potentially reduce the risk of more severe sequelae in high risk patients. Precious time is squandered with a ‘wait and see’ approach … resulting in unnecessary hospitalization, morbidity, and death. … In newly diagnosed, high-risk, symptomatic patients with COVID-19, SMDT has a reasonable chance of therapeutic gain with an acceptable benefit-to-risk profile.

Included in the paper is a “sequential multi-drug treatment algorithm” and summaries of the rationale and evidence for each component.

Dec 8, 2020: Appearing as a witness on Dec. 8, 2020, before the Senate Committee on Homeland Security and Governmental Affairs—which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”— Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on Ivermectin.

Related Ivermectin and COVID-19 Scientific Publications:

• Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 by Kory et al. accepted and published on American Journal of Therapeutics.
• A multi-centre randomised controlled study in Egypt (Elgazzar, Research Square) reported that the death rate was significantly lower in Ivermectin treated patients group (severe patients) vs non-Ivermectin group (2% vs 20%). 1,300 patients were included in this randomized controlled trial. 
• This randomized controlled trial out of Iran (Hashim, pre-print) used Ivermectin and Doxycycline in mild, moderate, and severe hospitalized COVID-19 patients. No patients in the mild and moderate COVID-19 category died and 18% of the severe patients perished taking this medication combo. In the control group, no mild-moderate patients died, but 27% of the severe COVID patients died. The patients who also got Ivermectin had a shorter recovery.
• A randomized, double-blind, placebo-controlled, multicenter, phase 2 clinical trial at five hospitals (Iran) and 180 patients with mild to severe disease (Niaee, ResearchSquare, Nov 2020). Ivermectin as an adjunct reduced the rate of mortality, the duration of low oxygen saturation, and the duration of hospitalization.
• The ICON study in US, published in Chest, Oct 2020 reported that Ivermectin treatment was associated with lower death rate vs Control (13.3% vs 24.5%) during treatment of COVID-19, especially in patients with severe pulmonary involvement.
• A double-blinded randomised controlled study in Bangladesh (Mahmud et al) reported that the death rate was 0% (0/183) in the Ivermectin arm vs 1.67% (3/180) in the control arm in mild to moderate COVID-19 patients.
• The IDEA (Ivermectin, Dexamethasone, Enoxaparin and Aspirin) study from Argentina reported 1 death out of 167 patients studied. The patient that died was a severe COVID-19 patient that required ventilator support.
• The pre-AndroCoV trial from Brazil reported that early detection of COVID-19 followed by a pharmaceutical approach with different drug combinations (Azithromycin, Hydroxychloroquine, Nitazonide, Ivermectin) yielded irrefutable differences compared to non-treated controls in terms of clinical outcomes, ethically disallowing placebo-control randomized clinical trials in the early stage of COVID-19 due to the marked improvements.
• A retrospective study out of Bangladesh (Khan, Archivos de Bronconeumologia 2020). This retrospective study enrolled a total of 325 from April to June 2020. 248 adult COVID-19 patients were looked at in two groups, 115 received ivermectin plus standard care (SC), while 133 received only standard care (SC). This study showed that Ivermectin was efficient at rapidly clearing SARS-CoV-2 from nasal swabs (median 4 days). This was much shorter than in the COVID-19 patients receiving only SC (15 days) or receiving a combination of three antiviral drugs (7–12 days). In addition, fewer Ivermectin patients developed respiratory distress leading to ICU admission. In fact, with Ivermectin, there was a quick hospital discharge (median 9 days) in 114 out of 115 patients; the one remaining patient had been admitted with advanced disease.

Ivermectin Contraindications

Asthma: Patients with a history of severe asthma should receive ivermectin with caution. Occasionally, systemic ivermectin has been reported to worsen bronchial asthma.

Hepatic disease: Although not extensively studied, due to its extensive hepatic metabolism, ivermectin should be administered with caution in patients with significant hepatic disease.

Human immunodeficiency virus (HIV) infection, immunosuppression: In patients with immunosuppression (including those with human immunodeficiency virus (HIV) infection) treated for intestinal strongyloidiasis, repeated ivermectin courses may be necessary. Adequate and well-controlled clinical studies have not been conducted in such patients to determine the optimal dosing regimen. Several treatments (i.e., at 2 week intervals) may be required and a cure may not be achievable. Control of extra-intestinal strongyloidiasis in these patients is difficult, however, suppressive therapy (i.e., once per month) may be helpful.

Pregnancy: Data with oral ivermectin use during pregnancy are insufficient to inform a drug-associated risk. Systemic exposure from topical use of ivermectin is much lower than from oral use. Four published epidemiology studies evaluated the outcomes of a total of 744 women exposed to oral ivermectin in various stages of pregnancy. In the largest study, 397 women in the second trimester of pregnancy were treated open-label with single doses of ivermectin or ivermectin plus albendazole; there was no observed difference in pregnancy outcomes between treated and untreated populations. However, these studies cannot definitely establish or exclude the absence of drug-associated risk during pregnancy, because either the timing of the administration during gestation was not accurately ascertained or the administration only occurred during the second trimester. In animal embyrofetal development studies of oral ivermectin given during organogenesis, adverse developmental outcomes, including cleft palate, exencephaly, wavy ribs, and clubbed forepaws, occurred at or near doses that were maternally toxic. Pre-implantation loss and abortion were also noted.

Breast-feeding: After oral administration, ivermectin is excreted in human breast milk in low concentrations. Excretion in human breast milk after topical administration has not been evaluated. According to the manufacturer, treatment with oral ivermectin in mothers who are breast-feeding should only be undertaken when the risk of delayed treatment to the mother outweighs the possible risk to the newborn. Previous American Academy of Pediatrics (AAP) recommendations considered oral ivermectin to be usually compatible with breast-feeding. The amount of ivermectin present in human milk after topical application has not been studied; however, systemic exposure from topical ivermectin use is much lower than from oral use. According to the manufacturer, discontinue nursing or discontinue the topical cream, taking into account the importance of the drug to the mother. Women who are breast-feeding while using topical ivermectin should avoid accidental transfer of ivermectin to the breast area where it might be directly ingested while nursing.

Children, infants: The topical administration of ivermectin to infants and children should be under the direct supervision of an adult to prevent ingestion of the lotion.

Onchodermatitis: Patients with hyperreactive onchodermatitis (i.e., sowda) may be more likely than others to experience severe edema and worsening of onchodermatitis after ivermectin use.

Source: https://www.pdr.net/drug-summary/Sklice-ivermectin-2415

Precautionary Note: Ivermectin has a number of potentially serious drug-drug interactions. Please check for potential drug interaction at Ivermectin Drug Interactions - Drugs.com. The most important drug interactions occur with cyclosporin, tacrolimus, anti-retroviral drugs, and certain anti-fungal drugs. 

Due to the possible drug interaction between quercetin and ivermectin (may increase ivermectin levels), these drugs should not be taken simultaneously (i.e. should be staggered morning and night). 

Ivermectin is also lipophilic and therefore, bioavailability is maximised on a full stomach; or best to be taken with meal.

NIH Recommendation on the Use of Ivermectin for the treatment of COVID-19

“The COVID-19 Treatment Guidelines Panel has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.” 

The FLCCC has published a public statement with a list of responses to the above NIH statement:

"We are grateful that the Panel has upgraded their recommendation from “against use” to a neutral stance that neither promotes nor discourages use of ivermectin by doctors. A similar neutral stance applies to monoclonal antibodies and convalescent plasma, both of which are widely used in COVID-19 treatment in the U.S."..

NIH Summary Description of the Evidence Base

“Some clinical studies showed no benefits or worsening of disease after ivermectin use, whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19, greater reduction in inflammatory markers, shorter time to viral clearance, or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.” 

FLCCC Response: We strongly object to suggesting that there is a clinical evidence of worsening disease with ivermectin use. The first three open label RCT’s (references 11–13) found no benefit with short duration of treatment (1–2 days) vs. early viral clearance when treatment was extended to five days. Only the observational study by Soto-Becerra et al. (references 14) reported contradictory findings of potential harm. This study consisted of a pharmacy database analysis which attempted to compare patient groups that received either hydroxychloroquine, azithromycin, or ivermectin (dosage and duration not reported) to those that received supportive care only. In each treatment group, a large number of early deaths occurred while none occurred in the control group, clearly indicating that the sicker and more imminently dying patients received some form of “experimental treatment.” If a study of this quality and design had instead somehow concluded a benefit for ivermectin, as evidence-based scientists and clinicians we would be among the first to rapidly dismiss it as biased or of limited interpretive power.

You can read the FLCC list of responses and conclusion at the FLCCC website.

Ivermectin Dosage in Humans for COVID-19 - FLCCC Protocol

PREVENTION PROTOCOL

Should I take ivermectin as a prophylaxis? For preventive measures, the Front Line COVID-19 Critical Care Working Group (FLCCC) I-MASK+ protocol recommends:

Anti-Virals & AntiSeptics

• Gargle mouthwash: 2 x daily – gargle (do not swallow) antiseptic mouthwash with cetylpyridinium chloride (e.g. Scope mouthwash™, Crest mouthwash, Colgate mouthwash) or povidone/iodine 1 % solution as alternative (e.g. Betadine® Antiseptic Sore Throat Gargle™). 
• lvermectin
• Chronic Prevention: 0.2 mg/kg per dose (take with or after a meal) — twice a week for as long as disease risk is elevated in your community (Ref)
• Post COVID-19 Exposure Prevention: 0.4 mg/kg per dose (take with or after a meal)  — one dose today, repeat after 48 hours.

Related: 

• BEST NASAL SPRAYS FOR COVID-19
• BEST MOUTHWASHES FOR COVID-19

Immune Fortifying / Supportive Therapy

• Vitamin D3: 1000–3000 IU/day. (Amazon) (iHerb)
• Vitamin C: 500 - 1,000 mg BID (twice daily) (Amazon) (iHerb)
• Quercetin: 250 mg daily.  (Amazon) (iHerb)
• Zinc: 30 - 40 mg/day (elemental zinc). Zinc lozenges are preferred. (Amazon) (iHerb)
• Melatonin: 6 mg before bedtime (causes drowsiness). (Amazon)

Ivermectin Alternative

• Nigella Sativa 40mg/kg daily (black seed) 

To be used if ivermectin not available or added to ivermectin for optimal prevention.

Notes:

• High risk Individuals: > 60 years with co-morbidities (hypertension, diabetes, chronic lung disease, chronic kidney disease), obesity, long term care facilities, etc.
• Post COVID-19 exposure: To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask.
• Precautionary Note: Ivermectin has a number of potentially serious drug-drug interactions. Please check for potential drug interaction at Ivermectin Drug Interactions - Drugs.com. The most important drug interactions occur with cyclosporin, tacrolimus, anti-retroviral drugs, and certain anti-fungal drugs. 
• Due to the possible drug interaction between quercetin and ivermectin (may increase ivermectin levels), these drugs should not be taken simultaneously (i.e. should be staggered morning and night). 
• Ivermectin is also lipophilic and therefore, bioavailability is maximised on a full stomach; or best to be taken with meal.
• Vitamin D3 RDA (Recommended Daily Allowance) is 800–1000 IU/day. The safe upper-dose daily limit is likely < 4000 IU/day. Vitamin D deficiency has been associated with an increased risk of acquiring COVID-19 and from dying from the disease. Vitamin D supplementation may therefore prove to be an effective and cheap intervention to lessen the impact of this disease, particularly in vulnerable populations, i.e. the elderly and obese.
• When Is the Best Time to Take Vitamin D? Morning or Night? It is possible that increasing vitamin D levels during the day may act, in part, as a signal that suppresses melatonin generation (source). Therefore, it's better to take vitamin D (with meal) during the day and melatonin to be taken just before bedtime.
• It is likely that vitamin C and quercetin have synergistic prophylactic benefit. Quercetin should be used with caution in patients with hypothyroidism and TSH levels should be monitored.
• Please consult with a qualified doctor and only use human ivermectin. Ivermectin for animals contain excipients (binding and storage compounds such as polyethylene glycol (PEG)) that are known to cause liver failure in high doses. 

Related: 

• List of Doctors that will prescribe Ivermectin

• List of Pharmacies that will fill Ivermectin

EARLY TREATMENT PROTOCOL

For early outpatient protocol (COVID-19 positive), the Front Line COVID-19 Critical Care Working Group, FLCCC I-MASK+ protocol recommends:

1. First line agents (use any or all medicines; listed in order of priority/importance)

Anti-Virals

• Ivermectin: 0.4–0.6 mg/kg per dose (take with or after meals) — one dose daily, take for 5 days or until recovered. (Find a Doctor). Use upper dose range if:  1) in regions with more aggressive variants; 2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors. (Ref)

• and/or Nitazoxanide: 500 mg 2 x daily for 5 days after meals. Combine with ivermectin (preferred) or substitute if ivermectin is not available. (Nitazoxanide is often unavailable or high-priced in the USA) (Ref).

Anti-Septic Anti-virals

• Antiviral mouthwash: Gargle 3 x daily (do not swallow; must contain chlorhexidine,  povidone-iodine, or cetylpyridinium chloride). (e.g. Scope mouthwash™, Crest mouthwash, Colgate mouthwash, Betadine® Antiseptic Sore Throat Gargle)
• Iodine Nasal Spray: Use 1 % povidone iodine commercial product as per instructions 2–3 x daily. If 1 %-product not available, must first dilute the more widely available 10 %-solution and apply 4–5 drops to each nose every 4 hours. (No more than 5 days in pregnancy)

Anti-Coagulants + Immune Fortifying

• Aspirin: 325 mg/day unless contraindicated. (Amazon)
• Vitamin D3: 5,000 IU daily. Preferred forms if available: Calcitriol (Rocaltrol) 0.5 mcg on day 1, then 0.25 mcg daily for 7 days – or Calcifediol 0.5 mg on day 1, then 0.2 mg on days  3 + 7, then 0.2 mg weekly until recovered.
• Melatonin: 10 mg before bedtime (causes drowsiness). (Amazon)

Synergistic Therapies

• Vitamin C: 500 - 1,000 mg BID (twice daily) (Amazon) (iHerb)
• Quercetin: 250 mg twice a day. (Amazon) (iHerb)
• Zinc: 100 mg/day. Zinc lozenges are preferred. (Amazon) (iHerb)

Nutritional Therapeutics (New)

• Curcumin (turmeric) 500mg 2 x daily for 14 days (Ref) (Amazon)
• Nigella Sativa 80mg/kg daily for 14 days (Amazon)
• Honey 1gram/kg daily for 14 days

Pulse Oximeter

FLCCC also recommend monitoring your oxygen saturation with a pulse oximeter and to go to the hospital if you get below 94%. (Amazon)

Other Alternatives: 

• Optional: Betadine nasal spray applied 3 times a day (Ref) (Amazon) 
• Optional: Xlear Nasal Spray with Xylitol: use twice a day (Ref) (Amazon)
• Optional: Azithromycin 250 mg twice a day. (Ref) (Find a Doctor). 
• Optional: Bromhexine 8 mg three times a day (Ref) (Lazada Malaysia*)

* Not available on Amazon

2. Second line agents (listed in order of priority /importance)

Add to first line therapies above if: 

1) ≥5 days of symptoms; 

2) Poor response to therapies above; 

3) Significant comorbidities

Dual anti-androgen Therapy

1. Spironolactone 100 mg 2 x daily for ten days
2. Dutasteride 2 mg on day 1, followed by 1 mg daily for 10 days. If dutasteride is not available, use finasteride 10 mg daily for 10 days.

Note: Dutasteride and finasteride are contraindicated in pregnancy.

Fluvoxamine

Fluvoxamine: 50 mg twice daily for 10 days. 
Consider fluoxetine (Prozac) 30mg daily for 10 days as an alternative (it is often better tolerated).
Avoid if patient is already on an SSRI.

Notes: 

• Combining fluvoxamine and melatonin may significantly increase the blood levels and effects of melatonin (Drugs.com). You can check for other potential drug interactions with fluvoxamine at Fluvoxamine Drug Interactions - Drugs.com.
• Some individuals who are prescribed fluvoxamine experience acute anxiety which needs to be carefully monitored for and treated by the prescribing clinician to prevent rare escalation to suicidal or violent behavior.

Monoclonal antibody therapy

Casirivimab/imdevimab: 600 mg each in a single subcutaneous injection for patients with one or more risk factors as follows: Age > 65y; obesity; pregnancy; chronic lung, heart, or kidney disease; diabetes; immunosuppressed; developmental disability; chronic tracheostomy; or tube feeding.

3. Third line agent 

To consider if after day 7–10 from first symptoms and patient has either: abnormal chest x-ray, shortness of breath, or oxygen saturations of 88–94%. If oxygen saturation is lower than 88%, emergency room evaluation should be sought.

Prednisone or Methylprednisolone: 1mg/kg daily for 5 days followed by slow taper or escalation according to patient response. 

Ivermectin Dosage Chart for Humans by body weight for prophylaxis and treatment of COVID-19 

NB: Ivermectin is lipophilic and therefore, bioavailability is maximised on a full stomach; or best to be taken with or immediately after a meal.

Check out the summary of evidence on Ivermectin versus COVID-19 from Ivmmeta.com (constantly updated).

For post-covid or long covid syndrome, check out FLCCC I-Recover Post-COVID Protocol. For a simplified version of the I-MASK+ protocol, the FLCCC has also developed the I-MASS protocol.

Ivermectin Dosage in Humans for COVID-19 - AAPS Protocol

For early outpatient protocol (COVID-19 positive), the AAPS (American Association of Physicians and Surgeons) recommends:

• Ivermectin 0.2 - 0.6 mg/kg [6-36 mg] single oral dose given daily or every other day for 2-3 doses.

Where can you find a doctor who will prescribe ivermectin?

1. Ask your doctor to prescribe it.
2. Try contacting PushHealth.com for a prescription
3. The FLCCC Alliance has a network of “Doctors who prescribe Ivermectin” who use the i-MASK and MATH+ protocols, and who may prescribe ivermectin and/or other useful medications for Covid-19.
4. America’s Frontline Doctors (aflds.com) also has a network of physicians who may be reached by telemedicine for an evaluation and possible prescription.
5. Text2MD favors the i-MASK protocol and will often prescribe ivermectin for their telemedicine patients.
6. EXSTNC.com – pronounced “existence”; they have a list of doctors and what drugs they typically prescribe for Covid-19, including many ivermectin-friendly doctors.
7. The Complete Guide To Health has a directory of doctors who may give ivermectin to their Covid-19 patients.
8. Here is a video from Dr. Mobeen Syed discussing different ways to find a doctor who will prescribe ivermectin for Covid-19.
9. use GoodRx to find low cost pharmacies to fill your prescription
10. This website “ivermectin24h” offers ivermectin but it takes about 4 weeks to arrive in the mail.

For a more comprehensive list in US (by State), check out List of Doctors that will prescribe Ivermectin.

Conclusion

In conclusion, we suggest that you discuss with your doctor before taking any medication or supplement/s. Do not self-medicate. Do not buy any medication online. Reading this article or doing your own online research does not make you an instant expert. There's much more to it than what we have just covered. Unless you are a medical professional, you might misinterpret or may not fully understand the full consequences of a medical decision and the breadth and depth of the subject by just a few hours of online research.

******************************

Where can you find over-the-counter supplements for COVID-19 prevention based on FLCCC prevention protocol?

Here is the list of related nutrients and products you can purchase online from Amazon. 

Be aware that most of the dosages are above the recommended dietary allowance (RDA) and therefore such dosages should not be maintained on a long term basis. 

Disclaimer: The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of third party sites. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.